BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

ReShape Medical Announces Results of Phase 1 U.S. Clinical Study for Weight Loss


6/17/2011 6:54:34 AM

ORLANDO, Fla., June 17, 2011 /PRNewswire/ -- ReShape Medical®, Inc. today announces results of its U.S. Phase 1 investigational clinical study. This feasibility study of thirty subjects assessed the safety and effectiveness of the ReShape Duo in conjunction with lifestyle modification in patients with a body mass index (BMI) of 30-40. After six months of therapy, 21 study participants treated with the ReShape Duo achieved an average of 32% excess weight loss and maintained much of this weight loss six months after the device was removed.

The prospective, randomized study was conducted by three principal investigators: Brian Quebbemann, MD, FACS, Center for Advanced Laparoscopic Surgery, Newport Beach, California; Jaime Ponce, MD, FACS, FASMBS, Hamilton Medical Center, Dalton, Georgia; and Emma Patterson, MD, FRCS, FACS, Legacy Good Samaritan Medical Center, Portland, Oregon.

The results of the study are being presented today at the American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting during the Emerging Technologies Session by Dr. Jaime Ponce. "The study results are very encouraging. Although more extensive clinical study remains necessary, this initial feasibility data suggest that the ReShape Duo could be an attractive option for patients not ready to make a decision for surgery or a permanent implant," said Dr. Ponce.

Dr. Brian Quebbemann, the first physician in the U.S. to treat patients with the ReShape Duo, added, "ReShape Duo may have an important role in the treatment of obesity as both a six-month jump-start to weight management as well as providing a key component of longer-term therapy."

"We are pleased with our recent U.S. data and look forward to continued investigation in a U.S. pivotal study," said Ken Charhut, ReShape Medical CEO. "There is a wide gap between conventional behavior modification and invasive surgery. The ReShape Duo bridges this gap with a reversible, non-surgical approach to weight loss."

About the ReShape Duo

ReShape Duo is a non-surgical, dual-balloon treatment designed for the millions of people who want weight loss support, without the invasiveness of surgery or side effects of drugs. The device occupies existing space in the stomach to reduce its capacity for food. The dual-balloon is designed to maximize space occupation in the stomach and conform to the stomach's natural anatomy for efficacy and stability. ReShape Duo is placed in the stomach during a 30-minute outpatient procedure using deep conscious sedation. The dual-balloon remains in the stomach for up to six months and is then removed.

About ReShape Medical®, Inc.

ReShape Medical is a development-stage medical device manufacturer headquartered in Southern California. The company is focused on the development of a non-surgical weight loss device that can be used as an aid in the treatment of obese or overweight patients.

For more information, visit reshapemedical.com.

SOURCE ReShape Medical, Inc.


Read at BioSpace.com

Related News

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->